Prevalence, distribution and correlates of endocervical human papillomavirus types in Brazilian women

International Journal of STD and AIDS

Volumn 21, Issue 2, 2010, Pages 105-109

  Lippman, S A ^a,b   Sucupira, M C A ^c   Jones, H E ^a,d   Luppi, C G ^e   Palefsky, J ^f   Van De Wijgert, J H H M ^a,g   Oliveira, R L S ^e   Diaz, R S ^c  

^a POPULATION COUNCIL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d NewYork Presbyterian Hospital   (United States)

^e FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Brazil; HPV type; Human papillomavirus; Sexually transmitted infections

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; BRAZIL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; SEXUALITY; UTERINE ENDOCERVIX; VAGINA FLORA; VIRUS DETECTION; VIRUS INFECTION; VIRUS TYPING; WART VIRUS;

ADOLESCENT; ADULT; BRAZIL; CERVIX UTERI; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; RISK FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 75449105651     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2009.008436     Document Type: Article

References (39)

1. World Health Organization. Human Papillomavirus and HPV Vaccines: Technical Information for Policy-makers and Health Professionals. Geneva: WHO, 2007
2. Ministério da Saúde, Instituto Nacional de Câncer, Coordenação de Prevenção e Vigilância de Câncer. Estimativa 2008: Incidência de Câncer no Brasil. Rio de Janeiro: Instituto Nacional de Câncer - INCA, 2007
3. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007;369:1693-702
4. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-70
5. Villa LL. Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine. Int J Infect Dis 2007;11 (Suppl. 2):S17-25
6. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63-73
7. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27
8. Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006;24 (Suppl. 3):S26-34
9. Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278-85
10. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121:621-32
11. de Sanjose S, Diaz M, Castellsague X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007;7:453-9
12. Clifford GM, Gallus S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005;366:991-8
13. Oliveira FA, Pfleger V, Lang K, et al. Sexually transmitted infections, bacterial vaginosis, and candidiasis in women of reproductive age in rural Northeast Brazil: a population-based study. Mem Inst Oswaldo Cruz 2007;102:751-6
14. Vaccarella S, Herrero R, Dai M, et al. Reproductive factors, oral contraceptive use, and human papillomavirus infection: pooled analysis of the IARC HPV prevalence surveys. Cancer Epidemiol Biomarkers Prev 2006;15:2148-53
15. Lippman SA, Jones HE, Luppi CG, Pinho AA, Veras MA, van de Wijgert JH. Home-based self-sampling and self-testing for sexually transmitted infections: acceptable and feasible alternatives to provider-based screening in low-income women in Sao Paulo, Brazil. Sex Transm Dis 2007;34:421-8
16. Madico G, Quinn TC, Rompalo A, McKee KT Jr, Gaydos CA. Diagnosis of Trichomonas vaginalis infection by PCR using vaginal swab samples. J Clin Microbiol 1998;36:3205-10
17. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004;324:17-27
18. Souza IE, Nicholson D, Matthey S, et al. Rapid epidemiologic characterization of cytomegalovirus strains from pediatric bone marrow transplant patients. Infect Control Hosp Epidemiol 1995;16:399-404
19. Bernard HU, Chan SY, Manos MM, et al. Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. J Infect Dis 1994;170:1077- 85
20. de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 1995;76 (Pt 4):1057-62
21. Qu W, Jiang G, Cruz Y, et al. PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems. J Clin Microbiol 1997;35:1304-10
22. Smits HL, Bollen LJ, Tjong AHSP, et al. Intermethod variation in detection of human papillomavirus DNA in cervical smears. J Clin Microbiol 1995;33:2631-6
23. Palefsky JM, Holly EA, Ralston ML, Jay N. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis 1998;177:361-7
24. StataCorp. Stata Statistical Software: Release 8.0. College Station, TX: Stata Corportation, 2003
25. Palefsky JM, Minkoff H, Kalish LA, et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst 1999;91:226-36
26. Instituto Brasileiro de Geografia e Estatística (IBGE). Censo Demográfico 2000. See http://www.ibge.gov.br/home/estatistica/populacao/ censo2000/ (last accessed January 2008)
27. Longatto-Filho A, Erzen M, Branca M, et al. Human papillomavirus testing as an optional screening tool in low-resource settings of Latin America: experience from the Latin American Screening study. Int J Gynecol Cancer 2006;16:955-62
28. Souza EPd. Epidemiologia da infecção genital por HPV e anormalidades na citologia cervical em mulheres jovens brasileiras. Doctoral Dissertation. UNICAMP, Campinas, Brasil, 2004
29. Nonnenmacher B, Breitenbach V, Villa LL, Prolla JC, Bozzetti MC. [Genital human papillomavirus infection identification by molecular biology among asymptomatic women]. Rev Saude Publica 2002;36:95-100
30. Trottier H, Mahmud S, Costa MC, et al. Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2006;15:1274-80
31. Bonanni P, Borealini S, Bechini A. Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence. Vaccine 2009;27(suppl. 1):A46-53
32. Vaccarella S, Franceschi S, Herrero R, et al. Sexual behavior, condom use, and human papillomavirus: pooled analysis of the IARC human papillomavirus prevalence surveys. Cancer Epidemiol Biomarkers Prev 2006;15:326-33
33. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA 2007;297:813-9
34. Figueroa JP, Ward E, Luthi TE, Vermund SH, Brathwaite AR, Burk RD. Prevalence of human papillomavirus among STD clinic attenders in Jamaica: association of younger age and increased sexual activity. Sex Transm Dis 1995;22:114-8
35. Mao C, Hughes JP, Kiviat N, et al. Clinical findings among young women with genital human papillomavirus infection. Am J Obstet Gynecol 2003;188:677-84
36. Watts DH, Fazzari M, Minkoff H, et al. Effects of bacterial vaginosis and other genital infections on the natural history of human papillomavirus infection in HIV-1-infected and high-risk HIV-1-uninfected women. J Infect Dis 2005;191:1129-39
37. Allsworth JE, Lewis VA, Peipert JF. Viral sexually transmitted infections and bacterial vaginosis: 2001-2004 National Health and Nutrition Examination Survey data. Sex Transm Dis 2008;35:791-6
38. Stanley M, Villa LL. Monitoring HPV vaccination. Vaccine 2008;26 (Suppl. 1):A24-7
39. Goldie SJ, Kim JJ, Kobus K, et al. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine 2007;25:6257-70